Our findings are consistent with other studies that have investigated the prognostic significance of HSD3B1 in prostate cancer.6,7,12 Hearn and colleagues6 were early investigators of patient outcomes by HSD3B1 genotype status in men who had received treatment with ADT.18 Those with the HSD3B1 CC genotype demonstrated worse progression-free survival, distant metastasis-free survival, and overall survival as a function of the number of adrenal-permissive alleles inherited in a primary cohort of 443 patients postprostatectomy and in 2 validation cohorts (post-prostatectomy and metastatic). This evidence concerns the gene HSD3B1 and Familial prostate cancer.